In a groundbreaking study published in The Lancet on March 5, 2026, researchers from Brown University’s School of Public Health uncovered striking shifts in medical prescribing behaviors following an unprecedented White House briefing that took place in September 2025. This briefing, which addressed the possible risks of acetaminophen (paracetamol) use during pregnancy in relation to autism and proposed leucovorin as a therapeutic avenue for autism spectrum disorder, appears to have precipitated rapid, nationwide changes in how physicians prescribe these drugs.
Analyzing extensive data derived from Cosmos, a massive electronic health record database encompassing over 1,600 hospitals and 37,000 clinics throughout the United States, the researchers employed rigorous data and statistical analysis to track weekly prescribing trends before and after the White House announcement. Prior prescribing patterns were used to construct expected trends, against which observed real-world behavior was compared. This methodology allowed for a highly detailed examination of alterations attributable to the public health communication event.
The September 22, 2025, briefing itself was highly unconventional in its direct federal engagement with medical prescribing customs. Administration officials conveyed an association between acetaminophen use during pregnancy and a purported increased risk of autism in offspring. Additionally, leucovorin, a folate-based medication primarily approved for certain oncology-related and metabolic conditions, was raised as a candidate for autism treatment. Importantly, leucovorin’s role in autism therapy remains investigational, supported only by preliminary, small-scale clinical trials with inconclusive findings, and it is not endorsed by any major autism clinical guidelines.
Following this announcement, the study documented an approximate 10% drop in acetaminophen prescriptions given to pregnant women in emergency room settings compared to projected levels. In the initial month, the reduction peaked at 16%, culminating in a pronounced 20% decline by the third week post-briefing. These declines occurred without any concurrent new clinical trial data or formal revisions to treatment guidelines, underscoring the powerful influence of political messaging on clinical decision-making.
Conversely, prescribing patterns for leucovorin among children aged 5 to 17 surged dramatically. The researchers noted a staggering overall increase of approximately 71% in outpatient leucovorin prescriptions beyond expected baselines. This effect was especially pronounced immediately following the briefing, with a 93% rise within the first month and a doubling of prescriptions during the second week. Notably, about 72% of these prescriptions were written for pediatric patients formally diagnosed with autism, a subgroup representing only around 4% of the pediatric cohort examined in the dataset.
This off-guideline uptick in leucovorin prescriptions, absent new high-quality clinical evidence, highlights the far-reaching impact that high-profile federal communications can exert on therapeutic choices nationwide. Dr. Michael Barnett, a corresponding author and professor at Brown University, emphasized that these shifts not only reflect patient influence but also suggest that physicians themselves integrated the briefing’s messaging into their clinical practice, bypassing standard evaluative processes.
The implications of these findings pose critical questions about the mechanisms through which politicized health information propagates into clinical environments. Unlike typical evidence dissemination, which undergoes peer review and guideline formation over extended periods, the White House briefing employed a direct-to-public approach that precipitated immediate behavioral changes in medicine. Such a phenomenon challenges the traditional frameworks of medical communication and evidence-based practice, raising concerns about premature adoption of unproven interventions.
Despite the extensive data analyses demonstrating strong associations between the briefing and prescribing trends, the authors prudently caution that causality cannot be definitively established within the study’s design. Furthermore, the research does not evaluate the clinical outcomes or potential benefits and harms experienced by patients as a result of these medication shifts, leaving open vital avenues for future investigation.
The study also sparks broader discourse on the responsibility of governmental entities and political leaders when disseminating divergent or incomplete medical information. “The White House briefing was an extremely unusual mechanism to communicate medical information and bypassed many standard checks on ensuring accurate messaging,” Barnett remarked. The rapid influence observed illustrates the power political figures can wield in steering health behaviors, sometimes circumventing scientific rigor and causing ripple effects throughout the healthcare system.
Emergency physician Dr. Jeremy Samuel Faust, also a study coauthor and assistant professor at Harvard Medical School, expressed astonishment at the magnitude of change. “It can take years, even decades, for high-quality research to finally reach clinicians,” Faust noted. “Here, by using the White House, it was done overnight. Unfortunately, they’re claiming breakthroughs that simply haven’t occurred.” His statement underscores the tension between scientific caution and political expediency in public health communication.
This landmark investigation underscores the necessity for more nuanced strategies in public messaging about health, especially when addressing sensitive conditions like autism, where evidence evolves gradually. It advocates for safeguarding the integrity of clinical decision-making from politicized pressures while highlighting the urgency for transparent, evidence-based discourse between policymakers, clinicians, and the public.
In sum, this study reveals an extraordinary phenomenon: a single White House briefing precipitated rapid, widespread changes in prescribing patterns for two distinct drugs related to pregnancy and autism, despite no new clinical evidence. This dynamic challenges established paradigms of how health knowledge flows into practice and invites a critical reassessment of the roles political institutions play within the medical information ecosystem.
Tags: acetaminophen use during pregnancy risksautism risk and medicationautism spectrum disorder prescribing changesBrown University public health studyCosmos electronic health records datafederal health communication impactleucovorin autism treatmentnationwide prescribing trendspregnancy medication guidelines updateprescribing patterns analysisstatistical analysis of medical prescriptionsWhite House autism briefing 2025